📈 The shift from external CDMOs to in-house operations accelerated processes and boosted antibody titers.
🧬 Utilizing transposons enhanced targeting of plasmids, reducing instability.
🔍 Better control of analytics strengthened communication with CDMOs and cut down validation times.
✨ Overall, this transition has yielded significant efficiency gains.
Introduction:
The article discusses the strategic decision made by the Danish antibody manufacturer Genmab to insource their cell-line development, emphasizing the improvements achieved in their biomanufacturing processes. This shift from reliance on contract development and manufacturing organizations (CDMOs) has resulted in enhanced antibody titers and efficiency in communication and collaboration with their manufacturing partners.
- Genmab’s decision to insource cell-line operations has accelerated development timelines and improved antibody yields.
- The motivation for insourcing stemmed from the company’s growth, making it feasible to handle cell-line development internally.
- The accelerated processes observed during the COVID-19 pandemic inspired Genmab to apply similar efficiencies to their oncology products.
- Utilizing targeted integration techniques, the company improved the stability of clones while decreasing the need for extensive screening.
- In-house analytics fostered better communication and trust with CDMOs, facilitating quicker validations and reducing redundant work.
Conclusion:
By insourcing cell-line development, Genmab has not only improved operational efficiencies and product yields but has also positioned itself better in its collaborations with manufacturing partners. This strategic shift underscores the potential for smaller biotech firms to leverage internal capabilities as they scale, enhancing both their development timelines and overall competitiveness in the biomanufacturing sector.
